Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus TAC ‐ skin atrophy ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.33 [0.01, 7.72]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus TAC ‐ charring ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 7
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus verapamil ‐ pain at injection site ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 5
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus verapamil ‐ charring ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 7
Studies not reported
Very low
Effectiveness of treatment · health problem or population
3 findings from 1 review
no estimate extracted
1 study · 74 participants
Very low
no estimate extracted
1 study · 74 participants
Very low
OR 1.26 [0.4, 3.93]
1 study · 51 participants
Low
Adverse events · health problem or population
1 finding from 1 review
Psychological outcomes ‐ not reported · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Analgesia requirements · health problem or population
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale)
1 finding from 1 review
no estimate extracted
6295 participants
Low
FUNCTIONAL LIMITATIONS
1 finding from 1 review
no estimate extracted
6004 participants
Moderate
*The anticipated absolute effects without exercise come from the range of outcomes at
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Continuous abstinence rate at
2 findings from 1 review
Percentage days with substance use at
2 findings from 1 review
Consumed amount at post‐treatment Lower SMD favors MBI
1 finding from 1 review
Craving
2 findings from 1 review
Secondary outcome: acceptability of treatment
1 finding from 1 review
Comparison intervention · relapsing multiple sclerosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
— · relapsing multiple sclerosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Interferons or glatiramer acetate · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
HR 0.86 [0.52, 1.42]
853 participants
Very low